Clinical Trial Update: Toripalimab Combined With SBRT for NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab in combination with stereotactic body radiotherapy for non-small cell lung cancer is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non-small Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING